Market Place
Sourcing Support
All News #Library
Biotech
Agomab Secures U.S. Patent for Inhaled ALK5 Inhibitor AGMB-447
26 Mar 2026 //
GLOBENEWSWIRE
Agomab Announces Closing Of Initial Public Offering
09 Feb 2026 //
GLOBENEWSWIRE
AgomAB Announces Pricing Of Initial Public Offering
05 Feb 2026 //
GLOBENEWSWIRE
Agomab Announces Launch Of Initial Public Offering
02 Feb 2026 //
GLOBENEWSWIRE
Belgium Biotech Agomab Seeks $212M Nasdaq Debut
29 Jan 2026 //
FIERCE BIOTECH
Immunology Biotech Agomab, Eye-Focused Spyglass Share IPO Plans
19 Jan 2026 //
FIERCE BIOTECH
Agomab Launches IPF Cohort After AGMB-447 Ph 1 Interim in Healthy
08 Jan 2026 //
GLOBENEWSWIRE
Agomab Reports Positive Phase 2A Results For Ontunisertib
17 Nov 2025 //
GLOBENEWSWIRE
Stenova Data at Digestive Disease Week 2025 Show AGMB-129 Potenti
06 May 2025 //
GLOBENEWSWIRE
Agomab Reports Positive Ph 2a Data For AGMB-129 In Crohn’s Disease
10 Mar 2025 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.